Signpath Pharma competitorsClear all

Signpath Pharma's top competitors include Del Mar Pharmaceuticals, Ablynx, Merrimack Pharmaceuticals and Karyopharm Therapeutics.
Signpath Pharma
Signpath Pharma
SignPath Pharma is a biotechnology company that develops products to treat cancer and mitigate drug-induced cardiac arrhythmia.
Del Mar Pharmaceuticals
Del Mar Pharmaceuticals
DelMar Pharmaceuticals is engaged in developing and commercializing therapies for the treatment of cancer patients.
Ablynx
Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Karyopharm Therapeutics
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
Founding Date
Founding Date
2006
Founding Date
2010
Founding Date
2001
Founding Date
2000
Founding Date
2008
Type
Type
Private
Type
Public
Type
Subsidiary
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Sandy, US HQ
Locations
San Diego, US HQ
Vancouver, CA
Menlo Park, US
Locations
Gent, BE HQ
Gent, BE
Locations
Cambridge, US HQ
Locations
Newton, US HQ
München, DE
Tel Aviv Yafo, IL
Employees
Employees
8
Employees
250% decrease
Employees
4061% increase
Employees
2763% decrease
Employees
424
Valuation ($)
Valuation ($)
N/A
Valuation ($)
15.4 m
Valuation ($)
N/A
Valuation ($)
51.8 m
Valuation ($)
N/A
Twitter followers
Twitter followers
36
Twitter followers
N/A
Twitter followers
254
Twitter followers
1.1 k
Twitter followers
N/A
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
349383
Alexa Website Rank
318239
Alexa Website Rank
388656
Alexa Website Rank
169517
Employee Rating
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
3.1
Employee Rating
3
Employee Rating
3.7

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
€85.2m (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
$40.9m (FY, 2019)
Net income
Net income
N/A
Net income
N/A
Net income
(€1.1m) (FY, 2016)
Net income
($17.3m) (FY, 2019)
Net income
($199.6m) (FY, 2019)

Funding

Total funding raised
Total funding raised
$ 5.3m
Total funding raised
$ 19.5m
Total funding raised
$ 498.8m
Total funding raised
$ 79.4m
Total funding raised
$ 248.7m
For sources of this data, please see the company profile

View company profiles

Del Mar Pharmaceuticals
HQ
San Diego, US
Employees
2↓ 50% decrease

DelMar Pharmaceuticals is engaged in developing and commercializing therapies for the treatment of cancer patients.

View company
Ablynx
HQ
Gent, BE

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.

View company
Merrimack Pharmaceuticals
HQ
Cambridge, US
Employees
27

Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.

View company
Karyopharm Therapeutics
HQ
Newton, US

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.

View company